

1 **Socio-medical Factors Associated with Neurodevelopmental Disorders on the Kenyan**
2 **Coast**

3 **Authors**

4 Patricia Kipkemoi^{1,2,3}, Jeanne E. Savage², Joseph Gona¹, Kenneth Rimba¹, Martha Kombe¹,
5 Paul Mwangi¹, Collins Kipkoech¹, Eunice Chepkemoi¹, Alfred Ngombo¹, Beatrice Mkubwa³,
6 Constance Rehema¹, Symon M. Kariuki^{1,5,6}, Danielle Posthuma^{2,4}, Kirsten A. Donald^{7,8}, Elise
7 Robinson^{9, 10}, Amina Abubakar^{1,3,5,6}, Charles R Newton^{1,3,5,6}

8 **Author Affiliations**

9 ¹ Neuroscience Unit, KEMRI-Wellcome Trust Research Programme, P.O Box 230-80108,
10 Kilifi, Kenya

11 ² Complex Trait Genetics Department, Center for Neurogenomics and Cognitive Research
12 (CNCR) Vrije Universiteit Amsterdam, Netherlands

13 ³ Institute for Human Development, Aga Khan University, P.O. BOX 30270-00100, Nairobi,
14 Kenya

15 ⁴ Department of Child and Adolescent Psychology and Psychiatry, Complex Trait Genetics,
16 Amsterdam University Medical Centres, Vrije Universiteit Amsterdam, Amsterdam
17 Neuroscience, Amsterdam, The Netherlands

18 ⁵Department of Psychiatry, University of Oxford, Warneford Hospital, Warneford Ln, Oxford
19 OX3 7JX, United Kingdom

20 ⁶ Department of Public Health, Pwani University, P.O. BOX 195-80108, Kilifi, Kenya

21 ⁷Department of Paediatrics and Child Health, 4th Floor ICH Building, Red Cross War
22 Memorial Children's Hospital and University of Cape Town, Rondebosch, South Africa

23 ⁸Neuroscience Institute, University of Cape Town, Groote Schuur Hospital, Observatory,
24 South Africa

25 ⁹The Broad Institute of MIT and Harvard, Cambridge, MA, USA

26 ¹⁰Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA

27

28

29

30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 **Abstract**

32 **Background**

33 Neurodevelopmental disorders (NDDs) are a group of conditions with their onset during the
34 early developmental period and include conditions such as autism, intellectual disability and
35 attention deficit hyperactivity disorder (ADHD). Occurrence of NDDs is thought to be
36 determined by both genetic and environmental factors, but data on the role of environmental
37 risk factors for NDD in Africa is limited. This study investigates environmental influences on
38 NDDs in children from Kenya. This case-control study compared children with NDDs and
39 typically developing children from two studies on the Kenyan coast that did not overlap.

40 **Methods and Findings**

41 We included 172 of the study participants from the Kilifi Autism Study and 151 from the
42 NeuroDev Study who had a diagnosis of at least one NDD and 112 and 73 with no NDD
43 diagnosis from each study, respectively. Potential risk factors were identified using
44 unadjusted univariable analysis and adjusted multivariable logistic regression analysis.
45 Univariable analysis in the Kilifi Autism Study sample revealed hypoxic-ischaemic
46 encephalopathy conferred the largest odds ratio (OR) 10.52 (95%CI 4.04 – 27.41) for NDDs,
47 followed by medical complications during pregnancy (gestational hypertension & diabetes,
48 eclampsia, and maternal bleeding) OR: 3.17 (95%CI 1.61 – 6.23). In the NeuroDev study
49 sample, labour and birth complications (OR: 7.30 (2.17 – 24.61)), neonatal jaundice (OR:
50 5.49 (95%CI 1.61 – 18.72)) and infection during pregnancy (OR: 5.31 (1.56 – 18.11))
51 conferred the largest risk associated with NDDs. In the adjusted analysis, seizures before age
52 3 years in the Kilifi Autism study and labour and birth complications in the NeuroDev study
53 conferred the largest increased risk. Higher parity, the child being older and delivery at home
54 were associated with a reduced risk for NDDs.

55 **Conclusion**

56 Recognition of important risk factors such as labour and birth complications could guide
57 preventative interventions, developmental screening of at-risk children and monitoring
58 progress. Further studies examining the aetiology of NDDs in population-based samples,
59 including investigating the interaction between genetic and environmental factors, are
60 needed.

61

62 **Introduction**

63 Neurodevelopmental disorders (NDDs) are a range of conditions affecting cognitive
64 and behavioural development, with notable examples being autism and intellectual disability.
65 ¹ Most NDD studies have been carried out in high-income settings, with a recent review of
66 global autism prevalence only including data from three African countries and other Africa-
67 based studies being smaller-scale case-control studies.² In much of the Global North, the
68 prevalence of autism has doubled, with the majority of this increase reflecting a change in
69 diagnostic practices.³ Globally, the prevalence of intellectual disability ranges from 0.1% to
70 1.6%, with variations observed based on the validity and reliability of survey questions and
71 data sources.⁴ Global epidemiological surveys have offered valuable insights into the
72 prevalence of autism and other NDDs, highlighting the necessity for epidemiology studies in
73 low- and middle-income settings to comprehend the global landscape of these conditions.²
74 Research indicates that the prevalence of NDDs, such as intellectual disability and autism, in
75 parts of Africa and other lower-middle-income countries (LMICs) may be higher due to
76 factors such as access to limited access to healthcare facilities and undernutrition,⁵ and other
77 risk factors for neuro-behavioural disorders such as adverse perinatal events, infections of the
78 brain and environmental toxins.⁶ which are more prevalent in these regions. ⁵ The same may
79 be true for the prevalence of autism in Africa, which is thought to be similar to the global
80 estimate or possibly greater given the high incidence of risk factors for neuro-behavioural
81 disorders such as adverse perinatal events, infections of the brain and environmental toxins.⁶

82 Environmental factors such as mode of delivery and birth weight have been associated
83 with the risk of NDDs, emphasising the multifactorial nature of these conditions.⁷ Additionally,
84 advanced maternal age, low maternal education, maternal alcohol and tobacco use, gestational
85 diabetes, and hypertension have been linked to an increased risk of intellectual disability.⁷
86 Studies have found prenatal factors, including uterine bleeding, certain medications during

87 pregnancy, low birth weight, and preterm delivery, to be associated with autism.⁸ Maternal
88 immune activation and elevated cytokines have been linked to an increased risk of NDDs.⁹
89 These prenatal factors are more common in LMICs; for example, in South Asia, preterm birth
90 accounts for more than 13% of the global burden of NDDs, and Africa contributes to 10% of
91 the burden.¹¹ This has changed little in the last decade. Evidence from population-based studies
92 in the Global North has identified the role of sociomedical risk factors in the aetiology of
93 autism.¹² There is limited evidence from African countries,⁶ with one study by Mankoski et al.
94 found evidence of falciparum malaria as a possible antecedent to autism in Tanzania ¹³. The
95 response to infections, such as malaria, may be an important contribution to this risk during
96 pregnancy that warrants further investigation. Widely researched risk factors associated with
97 NDDs, as reviewed by Guinchat et al., such as pre-eclampsia, placental insufficiency,
98 prolonged labour, induced labour, birth asphyxia, preterm birth and low birth weight, are
99 common in Africa.¹⁴ Bleeding and maternal infection during pregnancy have also been linked
100 to NDDs. There has been strong epidemiological evidence linking advanced parental age, both
101 maternal and paternal, to an increased risk for autism.¹⁵ Biological evidence, however, on
102 paternal-age-related de novo variants and the associated risk with autism and other conditions
103 has found small causal effects.¹⁶ There is also evidence that maternal age effects on *de novo*
104 variants are small.¹⁷ Lack of access to healthcare facilities leads to poor maternal health status,
105 which in turn can lead to higher incidences of NDDs.¹⁸


106 This study aims to identify prenatal, perinatal and postnatal factors associated with
107 NDDs, such as autism and intellectual disability in Coastal Kenya, comparing children with
108 autism to children with other NDDs as well as typically developing children. The study
109 examines data from two datasets: an ongoing case-control study that aims to characterise the
110 genetics and phenotypic architecture of NDDs in children (NeuroDev Study)¹⁹ and a study
111 aimed at validating an autism-specific screening tool and, after that, collecting data on risk

112 factors associated with autism (Kilifi Autism Study). Using a built-in replication approach, we
113 are able to robustly identify NDD risk factors in this socio-medical context, which has been
114 limited in Africa. Historically, research on autism has focused on the Global North;
115 environmental factors such as infectious diseases during pregnancy and limited healthcare
116 resources during pregnancy would allow the investigation of unique risk and protective factors
117 specific to Africa. These could potentially inform public health strategies towards the early
118 identification of autism in our settings.

119 **Methods**

120 **Study setting and participants**


121 This analysis draws participants from two datasets, namely the “The Kilifi Autism
122 study” and “The NeuroDev study”. The Kilifi Autism study was nested in a broader project to
123 adapt and validate autism screening and diagnostic tools for use among the populations living
124 in the Kenyan Coastal counties. The participants were recruited from mainstream schools,
125 special needs units, and special needs schools in Kilifi and Mombasa counties in Kenya
126 between 5th October 2012 to 20th September 2013. The sample included 268 children; 167
127 had a neurodevelopmental concern from teacher and caregiver reports, further delineated as
128 the autism group (n=78) and the NDD group (n=89) after administration of the Autism
129 Diagnostic Observation Schedule (ADOS), and 101 were reported to be typically developing
130 (Figure 1). Autism and intellectual disability co-occurred in some children (ID) (n=54, 19%).



138 Figure 1: autism only (n= 30), children with a presumptive diagnosis of only autism; ID only (n=89), children
139 with a presumptive diagnosis of (ID) only; autism and ID (n=54): TD (n=113), typically developing children in
140 the control group without any NDD.

141 The NeuroDev study is an ongoing case-control study set in Kilifi and Mombasa
142 Counties. The overall objectives include understanding the genetic and phenotypic

143 architecture of neurodevelopmental conditions in Africa, particularly in Kenya and South
144 Africa. The analysis sample consists of 72 children in the autism group, 93 in the NDD (ID
145 without autism) group and 72 in the typically developing group that are clinically diagnosed
146 (Figure 2). The study began data collection on 13th February 2019 and is ongoing, and this
147 analysis includes data collected up to March 2020, when the study paused its collection due
148 to the COVID-19 pandemic.



156 Figure 2: ASD only (n=38), children with a presumptive diagnosis of autism only; ID only (n=63), children with
157 a presumptive diagnosis of (ID) only; Autism and ID/Other NDD (n=50; TD (n=72), typically developing
158 children in the control group without any NDD.

159 Given that autism commonly co-occurs with intellectual disability in this setting, we
160 combined the diagnostic groups for analysis into NDD vs typically developing children.

161 **Study design and procedures**

162 *Kilifi Autism Study*

163 Eligible parents and children were recruited from mainstream schools, special needs
164 units and special schools after extensive community engagement efforts with the relevant

165 stakeholders in the health and education ministries. Typically developing children and children
166 with a presumptive diagnosis of NDD (autism, severe learning disabilities and intellectual
167 disability) from the Educational Assessment Resource Centre (EARC) were identified in the
168 special schools. We did not administer an IQ test to confirm cognitive ability. As such, we use
169 here the presumptive diagnosis for intellectual disability from the EARC.

170 Cases were identified from neurodevelopmental concerns from the teacher and
171 caregiver reports, as well as the presumptive diagnosis from the EARC. A trained fieldworker
172 shared information about the study and sought informed written consent to participate. A
173 positive screen on the social communications questionnaire (SCQ) or an endorsement of
174 autism from the ADOS or the DSM criteria was used to define autism case status. These
175 study measures were translated into the local languages, Kiswahili and Kigiriyama, through a
176 standardised forward and back translation process. A panel/team involved in translations
177 included a developmental psychologist and trained professionals (linguists and research
178 assistants) who were fluent in English, Swahili, and Kigiriyama and familiar with the local
179 culture.

180 *NeuroDev Study*

181 NeuroDev Kenya participants were recruited from previous studies, specialised
182 clinics, and special schools in Kilifi County. The cases and affected siblings included in the
183 NeuroDev study had clinical diagnoses of a neurodevelopmental disorder based on the DSM-
184 5 criteria or a presumptive diagnosis from EARC, were within the specified age range (2-17
185 years old) and were willing to participate. As with the Kilifi autism study, we did not
186 administer an IQ test prior to enrolment into the study. As such, we used the presumptive
187 diagnosis of intellectual disability from the EARC.

188 Participants were recruited from previous studies carried out in the Neuroscience unit
189 in Kilifi and from mainstream and special needs schools on the Kenyan coast. We included
190 cases with a diagnosis of at least one NDD and controls with no diagnosis of an NDD in this
191 current study. Cases were excluded if they had a co-occurring primary neuro-motor condition
192 such as cerebral palsy or Down syndrome. Controls were included in the study if they did not
193 have a diagnosis of a neurodevelopmental disorder, were within the study age range and were
194 matched according to catchment area, ancestry and age. Informed written consent to
195 participate in the study was sought from the parents or caregivers of children with or without
196 NDDs.

197 **Measures and assessments**

198 *Kilifi Autism Study*

199 The study team designed a socio-demographic questionnaire to collect information on
200 parental demographics, ethnicity, language, and educational attainment.

201 A medical and clinical history questionnaire was also used to collect information on
202 pregnancy, medication and drug use during pregnancy, birth order, birth weight, delivery and
203 post-natal complications, among others.

204 A special needs education specialist (JG) administered the ADOS and received
205 clinical training in administering and interpreting it. This study also administered a lifetime
206 version of the Social Communications Questionnaire (SCQ).

207 *NeuroDev Study*

208 The study collects data on demographics and socio-economic status through the use of
209 the Kilifi Asset Index.²⁰ A specialised neuromedical questionnaire was used to collect a
210 range of clinical features, including birth history, family history, growth, neurological

211 conditions, and medical conditions. Measures such as the Developmental Diagnostic
212 Dimensional Interview (3di), Swanson, Nolan and Pelham (SNAP)-ADHD rating scale and
213 the Ravens progressive matrices were used to evaluate autistic traits, ADHD traits, and non-
214 verbal reasoning, respectively.

215 **Socio-medical factors of interest**

216 We analysed the risk factors in the table below that have been noted as relevant and
217 linked to autism in previous studies. To reduce the number of tests we carried out, we
218 grouped some variables into larger categories. For example, maternal infection was
219 operationalised as a mother reporting a fever (yes/no) during pregnancy; for labour and birth
220 complications, this was operationalised as ‘Were there emergencies or problems during the
221 delivery?’ (yes/no) in the NeuroDev study, and if the mother/caregiver recalled this, we noted
222 the problem; these included complications such as induced labour and prolonged labour,
223 major obstetric haemorrhage, premature rupture of membranes (PROM), and umbilical cord
224 complications. In the Kilifi Autism study, this was operationalised in the following questions:
225 ‘Difficult or prolonged labour’. Parents/caregivers also noted any abnormality in the antenatal
226 and delivery periods. Hypoxic-ischaemic encephalopathy (HIE) is operationalised in this
227 study as no cry at birth for the child, difficulty and needing assistance to breathe after birth,
228 and not being able to suckle normally. Due to the limited recording of birth details in medical
229 records in many rural health facilities, we are not able to use Appearance Pulse Grimace
230 Activity Respiration (APGAR) scores. These are described in more detail in the table below.

231

232 *Table 1: Socio-medical factors of interest according to current literature.*

Environmental factors	Types of factors	Categories for analysis
------------------------------	-------------------------	--------------------------------

Parental factors	Mother's age (years) at birth	< 30 30 – 35 ≥ 35
	Father's age (years) at birth	< 30 30 – 35 35 – 40 ≥ 40
	Mother / Father's ethnicity	Giriama Chonyi Kauma Other Mijikenda Luo Other
	Mother and Father's education level	None Primary Secondary Tertiary
	Parental age gap	The difference between the father's and mother's age
	Birth order	Order in which a child was born, e.g. first born, second born or last born
	Birth weight	As reported by parents
	Number of children ever born	Children ever born in a family, whether dead or alive.
	Prenatal factors	Pregnancy medical complications
Pregnancy infections		Prenatal fever Malaria during pregnancy
Gestational term		< 38 weeks
Labour and birth complications		Induced labour Prolonged labour Premature rupture of membranes (PROM) Umbilical cord complications Major obstetric haemorrhage (MOH)
Hypoxic-ischaemic encephalopathy (HIE)		No cry at birth, difficulties breathing and breastfeeding
Delivery place		Delivery at home
Perinatal factors	Low birth weight	≤ 2.5 kg
	Family history of seizures	Parental reports of seizures in the family (first and second-degree relatives)

	Seizures disorders	Parental reports of seizures
	Neonatal jaundice	Parental reports of jaundice in the first 30 days of life
	Seizures in childhood	Before the age of 3 years
	Malaria in childhood	Malaria before age 3 years, Cerebral malaria anytime in childhood
	Head injury with and without loss of consciousness	Before the age of three years

233

234

Statistical Analysis

235

236

237

238

With the two datasets, we approached the analysis with a discovery and replication approach. When we compared the selection process and the demographic and clinical characteristics of the cases, there were enough similarities in the variables of interest to evaluate these two datasets using this approach.

239

240

241

242

243

244

245

246

247

248

Descriptive statistics were computed to describe the study sample according to diagnosis (Table 2). The potential for confounding effects of birth order, sex, and other variables was evaluated by first examining unadjusted associations between each potential confounder and the independent variables of maternal and paternal age as well as the dependent variable, autism case status. Unadjusted odds ratios (OR) with confidence intervals were computed to evaluate the magnitude of these associations, and unconditional logistic regression models were fit to estimate adjusted odds ratios and 95% confidence intervals (95%CI). Distribution difference for categorical variables was evaluated using chi-square tests for categorical variables and for analysis of variance for continuous variables compared with analysis of variance.

249

250

251

Exploratory analysis of the distribution of continuous variables and univariable analysis was carried out. Parametric tests such as Student's-t-test and non-parametric tests such as the Mann-Whitney U test were used on the raw scores of continuous variables. For categorical

252 variables, Pearson's chi-square test was performed (or Fisher's exact test if the frequency was
253 ≤ 5).

254 Our outcome (NDD diagnosis) is dichotomous; as such, we initially used an unadjusted
255 analysis of the potential risk factors using logistic regression of the risk factors of interest as
256 shown in the table above compared NDD vs TD children. We also computed the risk ratios
257 (RR).²¹ Risk factors with a p-value reaching 0.25 in the univariate analysis were included in
258 the multivariable analysis. For the multivariable analysis, parental and child characteristics
259 such as age, parental education level, and ethnicity were added *a priori* into the multivariable
260 model as covariates to account for any potential confounding of the other risk factors.

261 To address the issue of multiple comparisons in our study examining potential risk
262 factors associated with autism, we employed the Benjamini-Hochberg Procedure to control
263 the False Discovery Rate (FDR). This method is particularly suitable for situations where
264 many hypothesis tests are conducted simultaneously, as in this study with 35 tests. After
265 performing the necessary statistical tests to assess the association between each potential risk
266 factor and the outcome of interest in the unadjusted univariable analysis, we obtained a set of
267 p-values representing the significance of these associations. Specifically, we sorted the
268 obtained p-values in ascending order and calculated the critical value corresponding to our
269 desired FDR level (typically set at 0.05). Then, we compared each p-value to its
270 corresponding critical value and considered it significant if it fell below this threshold.

271 Analyses were conducted in STATA version 15.0 (StataCorp LP, College Station,
272 Texas, United States of America [USA]) and used package LOGITRISK to compute risk
273 ratios and the package METAN to estimate the effect size and standard error.

274 **Missing Data**

275 A number of parental variables had <10% of missingness, with paternal age at the
276 time of birth having the highest missingness (62% in the Kilifi Autism study and 38% in the
277 NeuroDev study). Maternal age at the time of birth was second highest in terms of
278 missingness, with 24% in the Kilifi Autism study and 11% in the NeuroDev study. Paternal
279 education was also highly missing in the Kilifi Autism study, at 24%.

280 **Ethics**

281 The Kilifi Autism study was approved in August 2012 by the Kenya Medical
282 Research Institute National Ethics and Review Committee (reference number:
283 KEMRI/RES/7/3/1). For the NeuroDev study, ethical approval was sought in Kilifi, Kenya,
284 and approval was granted by the Kenya Medical Research Institute Scientific Ethics and
285 Review Unit (KEMRI/SERU/CGMR-C/104/3629) in April 2018 and the Harvard T.H. Chan
286 School of Public Health IRB17-0600 in June 2018. Written consent was obtained from the
287 parents or caregivers of the child participants.

288

289 Results

290 Descriptive Characteristics of the Study Participants

291 The final sample from the Kilifi Autism study included 173 children with an NDD
292 diagnosis and 113 typically developing children (controls) with a median age of 10 years
293 (7,13), and for the NeuroDev study, 151 children with an NDD and 73 typically developing
294 controls with a median age of 11 years (9,13) (Table 2). More than half of the participants in
295 both studies were male (61.9% and 62.3% respectively). There were no statistically
296 significant differences in child sex and age between the diagnostic groups. In the Kilifi
297 Autism study, 41.8% of mothers did not have any formal schooling and 42.4% in the
298 NeuroDev study, in comparison to 13.2% of fathers and 14.8% of fathers in the two studies,
299 respectively.

300 In both the Kilifi Autism study and the NeuroDev study, the median ages of the
301 mothers of NDD children (37 years) were not statistically different ($p=0.376$; $p=0.530$,
302 respectively). Maternal age at delivery was not statistically different between the groups in
303 the two studies. In the NeuroDev study, the NDD group mothers had a similar median age
304 (26 years) to mothers of controls being aged 29 years ($p=0.560$). In the Kilifi Autism study,
305 we see no difference ($p=0.473$) in the median maternal age of birth at age 25 years for both
306 the NDD group and controls. For the NeuroDev study, we see that the ages of the NDD group
307 mothers are 26 years old, and mothers of controls have a median age of 29 years. The
308 difference in the ages is not statistically different ($p=0.560$). Maternal education levels were
309 statistically significantly higher in the NDD group compared to the typically developing
310 groups in both studies (Autism= $p<0.001$, NeuroDev, $p=0.018$).

311 Across both studies, groups did not differ in terms of most demographic
312 characteristics, such as father's and mother's age at assessment, paternal education levels (in
313 the NeuroDev study), and paternal age at delivery. There were significant differences in

314 prenatal and perinatal factors in the Kilifi Autism Study between the NDD and neurotypical
315 groups. For example, medical complications during pregnancy, such as gestational
316 hypertension, gestational diabetes, eclampsia and maternal bleeding, were reported more in
317 mothers of children with NDD (32.7%) as compared to mothers of neurotypical children
318 (13.3%), and this difference was statistically significant ($p < 0.001$). For the NeuroDev study,
319 infection during pregnancy (fever, malaria) was more common in the NDD group (18.4% v.
320 4.1%, $p = 0.003$) compared to the neurotypical group. For example, labour and birth
321 complications were also reported more in mothers of children with NDDs (17.4% v. 4.1%,

322 p<0.001), similar to HIE (16.6% v. 4.1%, p<0.001), low birth weight (<2.5kgs) (15.2% v. 1.4%, p <0.002), previous hospitalisation in
 323 childhood was also more commonly reported in children with NDDs (31.1% v. 13.7%, p=0.005).

324 *Table 2: Autism and NeuroDev Study Participant Characteristics*

325

Participant characteristics and socio-demographic data	Kilifi Autism study			NeuroDev Study		
	NDDs (n=173)	TD (n=113)	NDD vs TD p-value	NDDs (n=151)	TD (n=73)	NDD vs TD p-value
Child Sex Male	107 (61.9%)	66 (58.4%)	0.560 ^c	94 (62.3%)	37 (50.7%)	0.100 ^c
Child age in years at assessment (Median (Q1, Q3))	12 (9, 15)	9 (6, 11)	0.316 ^b	12 (10, 14)	11 (10, 12)	0.448 ^b
Mother's age in years (Median (Q1, Q3))	37 (32, 42)	34 (29, 40)	0.376 ^b	37 (32, 46)	40 (33, 45)	0.530 ^b
Maternal age at birth (Median (Q1, Q3))	25 (21, 31)	25 (21, 30)	0.473 ^b	26 (22, 33)	29 (23, 34)	0.560 ^b
<30	91 (52.6%)	58 (51.3%)	0.408 ^c	82 (54.3%)	29 (39.7%)	0.007^c
30-34	28 (16.2%)	12 (10.6%)		32 (21.2%)	16 (21.9%)	
>35	17 (9.8%)	11 (9.7%)		27 (17.9%)	12 (16.4%)	
Missing/Can't recall	37 (21.4%)	32 (28.3%)		10 (6.6%)	16 (21.9%)	
Father's age in years (Median (Q1, Q3))	45 (39, 52)	42 (36, 52)	0.490 ^b	46.5 (40.0, 55.5)	46 (42, 54)	0.489 ^b
Paternal age at birth in years (Median (Q1, Q3))	33.5 (29, 40)	31.5 (27.0, 41.0)	0.499 ^b	35 (29, 43)	35 (30, 43)	0.502 ^b
<30	21 (7.3%)	10 (8.9%)	0.024^a	28 (18.5%)	6 (8.2%)	0.026^a

30-34	25 (8.7%)	8 (7.1%)		20 (13.3%)	9 (12.3%)	
>35	9 (3.2%)	12 (10.5%)		54 (35.8%)	20 (26.2%)	
Missing/Can't recall	95 (33.2%)	83 (73.5%)		49 (32.5%)	38 (52.1%)	
Parental age gap in years: Median (Q1, Q3)	8 (3,11)	7.5 (4.5, 11.5)	0.544 ^b	7 (4, 11)	7 (4.5, 8.5)	0.477 ^b
Maternal education						
Never attended	44 (25.4%)	60 (53.1%)	<0.001^a	57 (37.8%)	38 (52.1%)	0.018^a
Primary	70 (40.5%)	35 (31.0%)		66 (43.7%)	33 (45.2%)	
Secondary	30 (7.3%)	3 (2.7%)		18 (11.9%)	2 (2.7%)	
Tertiary	7 (4.1%)	0 (0.0%)		5 (3.3%)	0 (0.0%)	
Missing/Can't recall	22 (12.7%)	15 (13.3%)		5 (3.3%)	0 (0.0%)	
Paternal education						
Never attended	16 (9.3%)	13 (11.5%)	0.013^a	20 (14.0%)	12 (37.5%)	0.350^a
Primary	62 (38.8%)	61 (54.0%)		74 (51.8%)	44 (60.3%)	
Secondary	34 (7.5%)	13 (11.5%)		31 (21.7%)	12 (16.4%)	
Tertiary	13 (5.9%)	3 (2.7%)		10 (7.0%)	1 (1.4%)	
Missing/Can't recall	48 (27.8%)	23 (20.4%)		8 (5.6%)	4 (5.5%)	
Ethnicity						
Giriama	65 (37.7%)	49 (43.4%)	<0.001^a	80 (53.0%)	50 (68.5%)	0.005^a
Chonyi	16 (9.3%)	21 (18.6%)		25 (16.6%)	17 (23.3%)	
Kauma	13 (7.5%)	10 (8.85%)		3 (2.0%)	3 (4.1%)	
Other Mijikenda	10 (5.8%)	12 (10.6%)		17 (11.3%)	3 (4.1%)	
Luo	6 (3.5%)	0 (0.0%)		6 (4.0%)	0 (0.0%)	
Other	41 (23.7)	6 (5.3%)		15 (9.9%)	1 (1.4%)	
Missing	22 (12.7%)	15 (13.3%)		5 (3.3%)	0 (0.0%)	
Number of children ever born: Median (Q1, Q3)	5 (3, 7)	6 (5, 8)	0.638 ^b	5.9 (2.66)	7.4 (2.3)	<0.001^b
Birth order: Median (Q1, Q3)	3 (2, 5)	4.0 (2.0, 5.5)	0.596 ^b	3.5 (2, 6)	5 (3, 7)	0.620 ^b
Medical complications during pregnancy (gestational hypertension,	50 (32.7%)	13 (13.3%)	0.001^c	11 (7.3%)	2 (2.7%)	0.230 ^c

diabetes, eclampsia and maternal bleeding)						
Infection during pregnancy (fever, malaria and other infections)	36 (23.7%)	20 (23.8%)	1.000 ^c	28 (18.4%)	3 (4.1%)	0.003^c
Drug misuse during pregnancy	17 (10.9%)	16 (17.9%)	0.124 ^c	14 (9.3%)	3 (4.1%)	0.281 ^c
Delivery place – home	91 (58.7%)	79 (46.5%)	<0.001^c	85 (56.7%)	63 (42.6%)	<0.001^c
Labour and birth complications (induced labour and prolonged labour, Premature rupture of membranes (PROM), major obstetric haemorrhage (MOH), umbilical cord complications and meconium aspiration)	29 (18.7%)	4 (4.0%)	<0.001^c	36 (17.4%)	3 (4.1%)	<0.001^c
HIE	56 (36.1%)	5 (5.1%)	<0.001^c	25 (16.6%)	3 (4.1%)	0.001^c
Birth weight in kgs (Mean, SD)	3.4 (1.16)	3.7 (0.68)	0.618 ^c	3.1 (2.5, 3.5)	3.5 (3.0, 3.6)	0.631 ^c
Low birth weight (≤ 2.5 kg)	27 (15.6%)	4 (3.5%)	<0.001^c	23 (15.2%)	1 (1.4%)	0.002^c
Previous hospitalisation in childhood	94 (60.7%)	19 (19.4%)	<0.001^c	47 (31.1%)	10 (13.7%)	0.005^c
Family history of seizures	15 (9.7%)	12 (12.2%)	0.538 ^c	34 (26.0%)	15 (22.1%)	0.605 ^c
Neonatal jaundice	15 (13.3%)	1 (0.9%)	0.410 ^c	28 (18.7%)	3 (4.1%)	0.002^c
Seizures at birth	9 (5.2%)	1 (0.9%)	0.047^c	23 (15.2%)	3 (4.1%)	0.017^c
Head injury or coma	16 (10.4%)	3 (3.1%)	0.048^c	Not assessed		
Malaria before 3 years	8 (4.6%)	4 (.5%)	0.450 ^a	Not assessed		
Seizures before 3 years	32 (18.5%)	2 (1.8%)	<0.001^a	Not assessed		
Family history of NDDs	Not assessed			15 (9.9%)	0 (0.0%)	0.002^c
Cerebral malaria anytime in childhood	Not assessed			16 (10.5%)	1 (1.4%)	0.014^c

327

328 **Risk factors comparison between NDD and Typically Developing groups:**

329 **Univariable Analysis**

330 Table 3 examines the unadjusted association between specific prenatal and perinatal factors
331 and NDDs. Of all the factors investigated for the unadjusted univariable analysis, eleven
332 factors in the Kilifi Autism study and eight factors in the NeuroDev study reached the
333 statistically significant cut-off of 0.05 after multiple testing corrections, as seen in Table 3,
334 highlighted in bold. Many of the factors conferred an increased risk for autism, with odds
335 ratio (OR) ranging from 1.05 to 12.60 in the Kilifi Autism study and 2.30 to 7.30 in the
336 NeuroDev study. Higher parity (more children born to a mother) (OR 0.84 (0.77 – 0.93; 0.78
337 (0.68 – 0.90) and decreasing birth order (OR 0.91 (0.82 – 0.99; 0.85 (0.75 – 0.95)) showed a
338 reduced risk for NDD in both studies). In a curious finding, ‘Delivery at home’ conferred the
339 most reduced risk for autism in both studies OR 0.32 (95%CI 0.18 – 0.59) and OR 0.21
340 (95%CI 0.10 – 0.44). To explore this result further, we controlled for maternal education
341 here, and we still see a protective effect with OR 0.28 (95%CI 0.13 – 0.70) and OR 0.24
342 (0.11 – 0.51) in the Kilifi Autism and NeuroDev studies, respectively. We adjusted here for
343 pregnancy and labour complications, and we see this protective effect persists in the
344 NeuroDev study with an OR of 0.28 (95%CI 0.13 – 0.65) but is statistically not significant in
345 the Kilifi Autism study (OR:0.57 (0.29 – 1.12). We pooled the ORs from both studies and
346 computed a meta-analysed OR, also in Table 3 below.

347 Further, we considered factors that reached the nominal threshold of $p \leq 0.25$; we included 15
348 factors in both the Kilifi Autism study and NeuroDev study, highlighted with superscript ^m
349 for multivariable analysis, where we further adjusted for parental characteristics.

350 *Table 3: Unadjusted analysis of relevant parental, perinatal and neonatal factors associated with autism – NDD vs Typically Developing*

	Kilifi Autism study				NeuroDev Study				
Risk factor variables	Odds ratio (95% CI)	p-value	Adjusted p-value	Risk Ratio (95%CI)	Odds ratio (95% CI)	p-value	Adjusted p-value	Risk Ratio (95%CI)	OR Meta-analysis from the two studies
Child Male sex	1.15 (0.71 – 1.87)	0.561	0.686	1.13 (0.73 – 1.72)	1.60 (0.91 – 2.82)	0.101	0.214 ^m	1.51 (0.92 – 2.39)	1.34 (0.03 – 2.65)
Child age in years at assessment (Median (Q1, Q3))	1.17 (1.10 – 1.25)	0.001	0.004^m	1.15 (1.09 – 1.22)	1.05 (0.95 – 1.16)	0.311	0.491	1.05 (0.96 – 1.14)	1.11 (0.02 – 2.19)
Mother's age in years (Median (Q1, Q3))	1.05 (1.02 – 1.09)	0.005	0.015^m	1.05 (1.02 – 1.08)	0.99 (0.95 – 1.02)	0.484	0.631	0.99 (0.96 – 1.02)	1.02 (0.02 – 2.02)
Maternal age at birth (Median (Q1, Q3))	1.02 (0.98 – 1.06)	0.433	0.621	1.02 (0.08 – 1.05)	0.98 (0.94 – 1.02)	0.232	0.387	0.98 (0.95 – 1.02)	1.00 (0.02 – 1.98)
<30	Reference group				Reference group				
30-34	1.49 (0.70 – 3.16)	0.301	0.452	1.42 (0.72 - 2.60)	0.71 (0.34 – 1.47)	0.355	0.507	0.73 (0.36 – 1.40)	0.96 (0.02 – 1.90)
>35	0.99 (0.43 – 2.25)	0.971	0.983	0.99 (0.46 – 2.00)	0.80 (0.36 – 1.77)	0.576	0.665	0.82 (0.39 – 1.64)	0.88 (0.02 – 1.90)

Father's age in years (Median (Q1, Q3))	0.99 (0.95 – 1.03)	0.537	0.682	0.99 (0.96 – 1.03)	1.00 (0.96 – 1.04)	0.960	0.982	1.00 (0.96 – 1.04)	0.99 (0.02 – 1.97)
Paternal age at birth in years (Median (Q1, Q3))	0.98 (0.94 – 1.02)	0.259	0.407	0.98 (0.95 – 1.02)	1.00 (0.97 – 1.02)	0.732	0.784	1.00 (0.97 – 1.02)	0.99 (0.02 – 1.96)
<30	Reference group				Reference group				
30-34	1.49 (0.50 – 4.45)	0.477	0.630	1.42 (0.53 – 3.31)	0.33 (0.10 – 1.12)	0.077	0.178	0.35 (0.11 – 1.11)	0.54 (0.01 – 1.07)
>35	1.15 (0.42 – 3.16)	0.785	0.836	1.13 (0.45 – 2.56)	0.78 (0.26 – 2.35)	0.658	0.757	0.80 (0.28 – 2.07)	0.93 (0.02 – 1.84)
Parental age gap in years: Median (Q1, Q3)	0.96 (0.91 – 1.01)	0.092	0.169 ^m	0.96 (0.92 – 1.01)	1.02 (0.96 – 1.08)	0.567	0.665	1.02 (0.96 – 1.07)	0.99 (0.02 – 1.96)
Maternal education ^m									
Never attended	Reference group				Reference group				
Primary	2.73 (1.55 – 4.78)	0.001	0.004	2.33 (1.17 – 3.47)	1.33 (0.74 – 2.40)	0.336	0.504	1.29 (0.76 – 2.11)	1.79 (0.04 – 3.54)

Secondary	4.64 (3.91 – 47.55)	0.001	0.004	3.30 (3.03 – 8.41)	6.00 (1.32 – 27.36)	0.021	0.077	4.00 (1.28 – 7.53)	5.23 (0.10 – 10.36)
Tertiary	1				1				
Paternal education ^m									
Never attended	Reference group				Reference group				
Primary	0.83 (0.37 – 1.86)	0.644	0.722	0.84 (0.40 – 1.71)	1.01 (0.45 – 2.26)	0.982	0.982	1.01 (0.48 – 2.01)	0.91 (0.02-1.80)
Secondary	2.13 (0.80 – 5.56)	0.128	0.211	1.91 (0.82 – 3.82)	1.55 (0.58 – 4.12)	0.380	0.518	1.47 (0.61 – 3.14)	1.79 (0.04 – 3.55)
Tertiary	3.52 (0.82 – 15.06)	0.090	0.169	2.81 (0.84 – 6.30)	6.00 (0.68 – 52.90)	0.107	0.214	4.00 (0.70 – 8.55)	4.44 (0.09 – 8.79)
Number of children ever born: Median (Q1, Q3)	0.84 (0.77 – 0.93)	0.001	0.004^m	0.85 (0.79 – 0.94)	0.78 (0.68 – 0.90)	0.001	0.010^m	0.80 (0.70 – 0.91)	0.81 (0.02 – 1.60)
Birth order: Median (Q1, Q3)	0.91 (0.82 – 0.99)	0.046	0.108 ^m	0.92 (0.84 – 0.99)	0.85 (0.76 – 0.95)	0.004	0.030^m	0.86 (0.79 – 0.96)	0.88 (0.02 – 1.74)

Medical complications during pregnancy (gestational hypertension, diabetes, eclampsia and maternal bleeding)	3.17 (1.61 – 6.23)	0.001	0.004^m	2.61 (1.52 – 4.09)	2.79 (0.60 – 12.93)	0.190	0.356	2.37 (0.63 – 5.90)	2.97 (0.06 – 5.88)
Infection during pregnancy (fever, malaria and other infections)	0.99 (0.53 – 1.86)	0.983	0.983	0.99 (0.56 – 1.71)	5.31 (1.56 – 18.11)	0.008	0.034^m	3.71 (1.48 – 6.68)	1.67 (0.03 – 3.30)
Drug misuse during pregnancy	0.56 (0.27 – 1.17)	0.122	0.211 ^m	0.59 (0.29 – 1.15)	2.38 (1.56 – 18.11)	0.008	0.034^m	2.09 (1.48 – 6.68)	0.91 (0.02 – 1.80)
Delivery place - home	0.32 (0.18 – 0.59)	0.001	0.004^m	0.34 (0.20 – 0.62)	0.21 (0.10 – 0.44)	<0.001	0.010^m	0.23 (0.11 – 0.47)	0.25 (0.01 – 0.50)
Labour and birth complications (induced labour and prolonged labour, PROM, umbilical cord complications and MOH)	5.41 (1.84 – 15.91)	0.002	0.007^m	3.75 (1.70 – 6.39)	7.30 (2.17 – 24.61)	0.001	0.010^m	4.48 (1.94 – 7.32)	6.21 (0.12 – 12.30)

HIE	10.52 (4.04 – 27.41)	0.001	0.004^m	5.39 (3.10 – 7.53)	1.00 (0.99 – 1.00)	0.055	0.138 ^m	1.00 (0.99 – 1.00)	1.83 (0.04 – 3.62)
Birth weight in kgs (Mean, SD)	1.00 (0.99 – 1.00)	0.001	0.004^m	1.00 (0.99 – 1.00)	0.52 (0.27 – 1.01)	0.053	0.138 ^m	0.55 (0.29 – 1.01)	0.68 (0.01 – 1.35)
Low birth weight (≤ 2.5 kg)	0.76 (0.56 – 1.04)	0.083	0.169 ^m	0.78 (0.59 – 1.04)	1.00 (0.99 – 1.00)	0.042	0.126 ^m	1.00 (0.99 – 1.00)	0.86 (0.01 – 1.35)
Previous hospitalisation in childhood	6.41 (3.53 – 11.62)	0.001	0.004^m	4.16 (2.82 – 5.64)	1 (Collinear)				N/A
Family history of seizures	0.77 (0.35 – 1.73)	0.583	0.687	0.79 (0.37 – 1.61)	1.24 (0.62 – 2.48)	0.546	0.665	1.21 (0.64 – 2.16)	0.86 (0.02 – 1.71)
Neonatal jaundice	2.14 (0.26 – 17.50)	0.477	0.630	1.92 (0.28 - 6.60)	5.49 (1.61 – 18.72)	0.007	0.034^m	3.79 (1.52 – 6.75)	3.08 (0.06 – 6.10)
Seizures at birth	6.15 (0.77 – 49.19)	0.087	0.169 ^m	4.06 (0.79 – 8.45)	4.23 (1.23 – 14.57)	0.023	0.077 ^m	3.20 (1.20 – 6.18)	5.01 (0.10 – 9.92)
Family history of NDDs	Not assessed				1(Collinear)				N/A
Cerebral malaria anytime in childhood	Not assessed				8.53 (1.11 – 65.65)	0.039	0.114 ^m	4.87 (1.10 – 8.79)	N/A

Head injury	3.67 (1.04 – 12.95)	0.043	0.108 ^m	2.90 (1.04 – 5.90)	Not assessed	N/A
Malaria before 3 years	1.32 (0.39 – 4.49)	0.656	0.722	1.28 (0.42 – 3.33)	Not assessed	N/A
Seizures before 3 years	12.60 (2.95 – 53.70)	0.010	0.028^m	5.83 (2.47 – 8.57)	Not assessed	N/A

351

352 Note: NDD= Neurodevelopmental Disorder, TD= Typically Developing, CI= Confidence Interval, Q1, Q3= Quartile 1, Quartile 3, SD= standard deviation (mean and SD are
353 provided for continuous variables with a normal distribution and median and Q1, Q3 are provided for count variables or continuous variables without normal distribution),
354 SE- standard error, * adjusted p values after Benjamini Hochberg Procedure to control the false discovery rate at 0.05, p-values in **bold** <0.05, p-values in ^{superscript m} ≤ 0.25
355 and included in multivariable analysis, effect sizes= meta-analysis of odds ratio from logistic regression

356 **Risk factors comparison between NDD and Typically Developing groups:**

357 **Multivariable Analysis**

358 Factors that reached the p-value threshold of ≤ 0.25 in the multivariable analysis were
359 selected for the multivariable model, and we adjusted for sociodemographic factors such as
360 maternal and paternal education and ethnicity.

361 *Kilifi Autism Study*

362 Ten factors reached the statistically significant threshold (Table 4), with seizures
363 before three years conferring the largest risk OR13.00 (3.02 – 55.90). HIE OR 9.54 (3.51 –
364 25.97), previous hospitalisation in childhood OR 6.19 (95%CI 3.25 – 111.79) and medical
365 complications during pregnancy (gestational hypertension & diabetes, eclampsia, and
366 maternal bleeding) OR 2.73 (95%CI 1.31 – 5.69) also indicated an association with NDDs.
367 Mother’s age in years was also significantly associated with NDDs. However, the odds were
368 small (OR 1.05 (1.01 – 1.08)). Delivery at home, labour and birth complications, head injury
369 and a few other factors, which were previously significant in the unadjusted analysis, were
370 not statistically significant in the multivariable analysis.

371 *NeuroDev Study*

372 Seven factors reached the statistically significant threshold with the adjusted
373 multivariable analysis. Labour and birth complications (OR 6.32 (1.81 – 22.03), infection
374 during pregnancy (OR 4.27 (1.20 – 15.16)) and alcohol use during pregnancy (OR 4.12 (1.08
375 – 15.75) conferred the largest risk associated with NDDs. Delivery at home was still
376 associated with a reduced risk (OR 0.29 (95%CI 0.13 – 0.64). We investigate this finding
377 further by adjusting for pregnancy and labour complications, and there is still a reduced risk
378 for NDDs (OR 0.35 (95%CI 0.15 – 0.79).

379

380 *Table 4: Adjusted multivariable analysis of relevant parental, perinatal and neonatal factors associated with autism after adjusting for parental*
 381 *socioeconomic and demographic status –NDD vs TD group.*

Risk factor variables	Kilifi Autism study			NeuroDev Study		
	Odds ratio (95% CI)	p-value	Risk Ratio (95%CI)	Odds ratio (95% CI)	p-value	Risk Ratio (95%CI)
Child Male sex	Not significant in univariable analysis			1.62 (0.89 – 2.94)	0.115	1.53 (0.90 -2.46)
Mother’s age in years (Median (Q1, Q3))	1.05 (1.01 – 1.09)	0.014	1.05 (1.00 – 1.08)	Not significant in univariable analysis		
Parental age gap in years: Median (Q1, Q3)	0.97 (0.91 – 1.03)	0.365	0.97 (0.92 – 1.03)	Not significant in univariable analysis		
Number of children ever born	0.96 (0.86 - 1.08)	0.521	0.96 (0.87 – 1.07)	0.84 (0.71 – 0.98)	0.031	0.85 (0.73 – 0.98)
Birth order	0.87 (0.01 - 0.97)	0.013	0.88 (0.01 – 0.97)	0.90 (0.80 – 1.02)	0.091	0.91 (0.82 – 1.02)

Medical complications during pregnancy (gestational hypertension, diabetes, eclampsia and maternal bleeding)	2.73 (1.31 – 5.69)	0.008	2.23 (1.27 – 3.87)	Not significant in univariable analysis		
Infection during pregnancy (fever, malaria and other infections)	Not significant in univariable analysis			4.27 (1.20 – 15.16)	0.025	3.21 (1.18 – 6.28)
Drug misuse during pregnancy	0.45 (0.20 – 0.98)	0.045	0.48 (0.22 – 0.98)	4.12 (1.08 – 15.75)	0.039	3.14 (1.07 – 6.36)
Delivery place - home	0.56 (0.28 – 1.10)	0.092	0.58 (0.30 – 1.09)	0.29 (0.13 – 0.64)	0.002	0.31 (0.14 – 0.66)
Labour and birth complications (induced labour and prolonged labour, PROM, umbilical cord complications and MOH)	2.83 (0.89 – 9.01)	0.079	2.39 (0.90- 5.00)	6.32 (1.81 – 22.03)	0.004	4.13 (1.67 – 7.10)
HIE	9.54 (3.51 – 25.97)	<0.001	5.15 (2.81 – 7.43)	1.00 (1.00 – 1.01)	0.158	1.00 (1.00 – 1.01)
Birth weight in kgs (Mean, SD)	0.70 (0.49 – 0.98)	0.040	0.72 (0.52 – 0.98)	0.46 (0.23 – 0.99)	0.047	0.49 (0.25 – 0.99)
Low birth weight (\leq 2.5 kg)	1.00 (0.99 – 1.00)	<0.001	1.00 (0.99 – 1.00)	1.00 (0.99 – 1.00)	0.272	1.00 (0.99 – 1.00)
Seizures at birth	6.79 (0.84 – 54.61)	0.072	4.30 (0.85 – 8.59)	3.35 (0.93 – 12.07)	0.064	2.71 (0.94 – 5.73)

Cerebral malaria anytime in childhood	Not assessed			7.57 (0.95 – 60.21)	0.056	4.57 (0.96 – 8.70)
Neonatal jaundice	Not significant in univariable analysis			6.56 (1.85 – 23.26)	0.004	4.23 (1.71 – 7.21)
Head injury	2.97 (0.77 – 11.46)	0.115	2.48 (0.79 – 5.60)	Not assessed		
Seizures before 3 years	13.00 (3.02 – 55.90)	0.001	5.01 (2.51 – 8.61)	Not assessed		

382 Note: NDD= Neurodevelopmental Disorder, TD= Typically Developing, CI= Confidence Interval, Q1, Q3= Quartile 1, Quartile 3, SD= standard deviation (mean and SD are
383 provided for continuous variables with a normal distribution and median and Q1, Q3 are provided for count variables or continuous variables without normal distribution),
384 SE- standard error, p-values in **bold** <0.05, p-values in ^{superscript m} ≤ 0.25 and included in multivariable analysis

385 **Discussion**

386 This study investigated the association of specific prenatal, perinatal and childhood
387 factors associated with autism and intellectual disability on the Kenyan coast. We found that
388 adverse prenatal, perinatal and childhood events were more common in children with NDDs
389 compared to typically developing children but that some of these were significant in the
390 discovery data (Kilifi Autism study) and not in the replication dataset (NeuroDev study). This
391 may be related to a number of factors including that these datasets were collected at different
392 time periods when the distributions may have differed, and differences in methodological
393 approaches in data collection scales used. These differences were reflected in the descriptive
394 analysis that showed distribution differences between NDD and TD groups for variables such
395 as higher levels of education status of mothers for the Kilifi autism study and reducing
396 proportion of older maternal age in the NeuroDev cohorts. These differences, among others,
397 may explain the findings that some associations with NDD were found in one dataset but not
398 the other.

399

400 ***Risk Factors***

401 In the unadjusted univariable analysis, the occurrence of seizures before three years of
402 age, HIE, labour and birth complications and previous hospitalisation in childhood were
403 increased in the NDD group compared to the TD group. Maternal age (older) in the Kilifi
404 Autism study and labour and birth complications, infection during pregnancy, neonatal
405 jaundice, cerebral malaria anytime in childhood and previous hospitalisation in childhood
406 emerged as statistically significant risk factors associated with autism in the NeuroDev study.
407 The multivariable analysis identified medical complications during pregnancy, such as
408 gestational hypertension and diabetes, eclampsia, maternal bleeding, HIE, and the mother's
409 age in years, were associated with NDDs in the Kilifi Autism study. However, this effect was

410 not replicated in the NeuroDev study, where labour and birth complications were not
411 significant risk factors in the Kilifi Autism study but were associated with autism in the
412 NeuroDev study.

413 Medical complications during pregnancy, such as gestational hypertension, diabetes,
414 and eclampsia, are complex problems in pregnancy that have been associated with autism and
415 other neurodevelopmental conditions.²² Some biological pathways have been postulated,
416 including a model of shallow placentation and an increase in placental debris in the maternal
417 circulation, which, thereby, leads to a maternal immune response that affects placental, foetal
418 circulatory systems and neurodevelopment.²³ Preeclampsia, for example, is moderated by
419 other underlying factors such as maternal age and maternal cardiovascular and metabolic
420 health.²⁴

421 Adverse perinatal events such as birth asphyxia are one of the leading causes of
422 neonatal mortality in low and middle-income countries and are linked to intellectual
423 disability, autism and cerebral palsy.²⁵ Studies have discussed hypoxic-ischemic damage, the
424 prolonged or acute oxygen deprivation that may affect brain regions that are especially
425 vulnerable to perinatal insults, which in turn contributes to inflammation and oxidative
426 damage.²⁶

427 Maternal infection during pregnancy has been found to increase the risk of autism
428 through the activation of the maternal immune response.²⁷ Population studies have singled
429 out viral infections in the first trimester, bacterial infections in the second trimester, and
430 influenza and febrile episodes in the entire pregnancy period, but especially in the third
431 trimester.²⁸ Our findings appear consistent with the literature, as we found maternal infection
432 during pregnancy to be a significant risk factor, with the effect persistent in the multivariable
433 analysis for the NeuroDev study.

434 Prolonged labour was the most noted labour and birth complication in the NeuroDev
435 study, with 22 mothers reporting this occurrence, major obstetric bleeding (n=8), and three
436 mothers also reported PROM. An American study found that children in the exogenous
437 oxytocin drug-administered group were 2.32 times more likely to exhibit an autism
438 phenotype. In contrast, another study in the US found that autism risk was not associated with
439 oxytocin use alone but when used with labour epidural analgesia.²⁹ Maternal age at birth also
440 conferred a smaller increased risk. In the Kilifi Autism study, labour and birth complications
441 were not statistically significant after the adjusted analysis (though they trended towards
442 significance) but were successfully replicated in the NeuroDev study.

443 Malaria before three years of age was associated with autism in Tanzania¹³, but we
444 did not find this association significant in the adjusted analysis. Interestingly, we see a strong
445 and persistent statistically significant association between seizures before age 3 years when
446 we compared the NDD and typically developing children in both univariable and adjusted
447 analyses. Malaria is one of the most common parasitic infections in our setting and the most
448 common cause of seizures in children under 5 years.³⁰ Brain MRI findings in a study in
449 Uganda gave evidence for ischaemic neural injury upon exposure to cerebral malaria and
450 other infections, which may be a pathway of interest in autism and other NDDs.³¹ This
451 requires further investigation.

452 Neonatal jaundice is associated with NDDs in the NeuroDev study. A population
453 study in Denmark found that exposure to jaundice in neonates born at full term (≥ 38 weeks)
454 was linked to an increased risk of developmental disorders.³² A study in Egypt also found a
455 similar association in a sample of 80 autistic children.³³ The impact of elevated serum
456 bilirubin levels on neurodevelopment has been a significant concern in both clinical practice
457 and scientific research.³⁴ A multisite case-control study in the US also found this association
458 between jaundice and autism in neonates born between 35-37 weeks.³⁵ A systematic review

459 of low-risk bias studies consolidated findings from 32 studies examining the association
460 between neonatal jaundice and autism and found limited convincing evidence of an
461 association between neonatal jaundice and autism.³⁶

462 Maternal education, one of the parental factors that was adjusted for in the
463 multivariable analysis, is important to investigate fully. Studies have found that parental
464 educational level and other socioeconomic markers may affect the awareness of autism as a
465 condition and help-seeking behaviour due to concerns about their child's development.³⁷ In
466 our analysis, maternal education was associated with delivery place; mothers with higher
467 education levels gave birth in hospitals as opposed to giving birth at home. We also see an
468 association between maternal education level and autism diagnosis, with mothers of autistic
469 children having higher education levels, supporting the link between maternal education and
470 developmental concerns.

471 Low birthweight and drug misuse emerged as important across the two datasets in the
472 multivariable analysis, but the associations for the latter were conflicting between the
473 datasets. Associations between substance use and NDDs are reported in other studies.³⁸
474 Intra-utero exposure to alcohol and tobacco is also thought to affect brain development and
475 function through targets in the intrauterine environment.³⁹ The conflicting results for drug
476 misuse across the datasets may be explained by spurious findings from the few observations
477 and temporal imprecision of exposure in the Kilifi Autism study.

478 Interpretation of these risk factors individually may be difficult as the biological
479 mechanisms of these factors are very likely closely related. For example, maternal bleeding
480 during pregnancy is associated with foetal hypoxia, which is, in turn, related to the risk of
481 autism.^{26,40} Foetal distress, gestational hypertension, prolonged labour, and cord
482 complications are also correlated with foetal hypoxia, and all these are associated with autism
483 risk.⁴¹ The shared biological pathway for these factors is postulated to be oxygen deprivation

484 during development.⁴¹ Prenatal complications are hypothesized to occur as a result of autistic
485 or neurodevelopmental conditions or a combinatory effect with genetic factors.⁴² There are
486 studies that have found that there are genetic factors associated with febrile seizures,
487 infections such as meningitis and even neonatal jaundice.⁴³ Recent research has also focused
488 on the foetus' involvement in the birth process, with studies finding that the foetus actively
489 engages in the birth process through various physiological mechanisms.⁴⁴ These studies
490 highlight the entanglement between genetic and environmental factors. More studies are
491 required to investigate this interplay.

492

493 Sex and preterm birth were not statistically significant replicated risk factors
494 associated with autism after the adjusted multivariable analysis in this study. Maternal age
495 confers a slight increase in odds of NDDs in the Kilifi Autism study but not in the NeuroDev
496 study. A meta-analysis by Wu et al. found that in approximately 30 studies, there was an
497 increased risk of approximately 40% and 50% for the oldest maternal and paternal age
498 categories.⁴⁵ Studies have also shown increases in risk for maternal age above 35 years and
499 above paternal age of 40 years.⁴⁶ Plausible suggestions have been made regarding the
500 combined effect of maternal and paternal age, though the mechanisms of these changes are
501 not as well elucidated. Potential explanations include epigenetic modification and DNA
502 damage due to ageing and mediation due to pregnancy complications.

503

504 ***Protective Factors***

505 Even with the adjusted analysis, delivery at home still was associated with the most
506 reduced risk OR 0.31 (95%CI 0.12 – 0.80). The Kenyan government has increased efforts in
507 the past few decades to increase hospital access to mothers with the introduction of the Free
508 Maternity Policy in 2013, and in 2014, 52.3% of women in Kilifi County gave birth at a

509 health facility.⁴⁷ For mothers giving birth at home, long distance from a healthcare facility is
510 one main reason cited, which is compounded by limited access to transport services and poor
511 road networks.⁴⁸ The protective effect observed with delivery at home in our study warrants
512 more disentangling, as it may suggest that mothers of children with NDDs tend to have
513 higher education levels and may be aware of the potential of obstetric complications during
514 birth, leading them to give birth in a hospital setting. This association may not be causal, as it
515 simply shows that mothers of children with autism and neurodevelopmental disorders
516 (NDDs) tend to have higher education levels and may be aware of the potential of obstetric
517 complications during birth, leading them to give birth in a hospital setting. Another plausible
518 explanation is that with limited resources and access to health care, mothers who had a
519 pregnancy with fewer complications may have considered themselves unlikely to have
520 complications during labour and birth and, as such, would more readily give birth at home as
521 opposed to those with pregnancy complications, who would likely present themselves to
522 hospital for labour and birth as they perceived themselves as “at risk”.⁴⁹ Higher parity (the
523 more children a mother had) and child age (the child being older) at assessment seemed to
524 confer a protective effect when we compared the NDD and TD groups. The association of
525 earlier order of birth order and reduced risk for NDD is consistent with findings from another
526 study⁵⁰ as well as having more children and NDDs observed in the replication, the NeuroDev
527 cohort appears to support the findings on the role of birth order in autism (discussed in
528 discovery dataset above). This is likely because of reproductive stoppage, whereby parents of
529 children with NDDs might pause or stop expanding the family after having a child with an
530 NDD.⁵¹

531 There is also an opportunity to investigate risk and protective factors in prospective
532 study designs to understand better factors that can connect brain and behaviour change and
533 interventions due to these modifiable factors.⁵²

534 ***Strengths and limitations of the study***

535 With this study, we add much-needed data regarding environmental factors associated
536 with NDDs in countries on the African continent, and with the use of the within-study
537 approach, we were able to evaluate the replication of the risk factors with another data set.
538 There are some limitations, particularly with the reliance on recall data as opposed to precise
539 measurement data on health cards and medical reports. There is a lot of missing data, such as
540 APGAR scores and accurate birth weight. This may have led to over or underreporting of
541 certain risk factors.

542 The Kilifi Autism Study and the NeuroDev Study were conducted at different times,
543 which may introduce temporal biases. Changes in healthcare access and environmental
544 factors over time could affect the comparability of the data. This temporal discrepancy might
545 influence the observed associations between environmental exposures and NDDs. The
546 criteria and processes used to diagnose and classify NDD cases vary slightly between the
547 Kilifi Autism Study and the NeuroDev Study.

548 Because of our modest sample size, we were not able to interrogate specific risk
549 factors, which were grouped into another variable, for example, hypertensive disorders,
550 eclampsia and maternal bleeding, which were grouped into medical complications during
551 pregnancy. It would also have been useful to investigate emerging risk factors such as
552 maternal mental health and general parental psychiatric history, which is a significant
553 confounding factor for perinatal risk factors and NDDs.

554 We were also unable to incorporate genetic results and other potential biomarkers,
555 such as neuroimaging. We were also missing information on other biological measures of
556 infection and inflammation in pregnancy and nutritional factors, such as iron deficiency in
557 pregnancy and early childhood.

558 ***Conclusion and clinical and research implications***

559 In conclusion, the study identified labour and birth complications as a pervasive significant
560 risk factor associated with NDDs. Further studies looking into the aetiology of autism,
561 particularly ones that examine genetic and environmental interaction, are encouraged. In the
562 NeuroDev study, we will have the opportunity to incorporate some genetic findings in our
563 further evaluation of risk factors. Recognition of prenatal, perinatal and childhood risk factors
564 is important clinically and in research as these factors hold the promise of guiding
565 developmental screening and monitoring to aid in earlier identification and screening of
566 autism, thereby reducing the delay in diagnosis and aiding quicker diagnosis and referral to
567 care.

568

569 **Acknowledgements**

570 We express our immense gratitude to the Kilifi Autism Study and NeuroDev Kenya
571 participants who volunteered to participate in these studies. We would also like to thank all
572 the study staff in KEMRI-Wellcome Trust involved in the study.

573 **Funding**

574 The Kilifi Autism study was funded through the Cheryl & Reece Scott Professorship Award
575 to Prof. Charles Newton. NeuroDev is supported by the Stanley Center for Psychiatric
576 Research at the Broad Institute, a grant from SFARI (704413), and by the National Institute
577 of Mental Health of the National Institutes of Health under Award Number U01MH119689.
578 Research reported in this publication was also supported by the Eunice Kennedy Shriver
579 National Institute of Child Health & Human Development of the National Institutes of Health
580 under Award Number R01HD102975. The content is solely the responsibility of the authors
581 and does not necessarily represent the official views of the National Institutes of Health.

582 **Author Contributions**

583 AA, JG and CRN contributed to the conceptualisation of the Kilifi Autism Study and AA,
584 CRN, KAD and ER contributed to the conceptualisation of the NeuroDev study. JG, KR,
585 MK, EC, AN, BM, CR, and PK were involved in data collection in the two studies. PM, CK
586 and PK handled data management curation. Formal analysis was conducted by PK with
587 supervision from JES, CRN, AA and ER. Funding acquisition was managed by AA, CRN,
588 ER, and KAD. The methodology was developed by PK, JES, AA, and CRN. The NeuroDev
589 project administration was overseen by EC. PK wrote the original draft, and all authors
590 contributed to the review and editing of the manuscript.

591 All authors accept the responsibility to submit this manuscript for publication.

592 **Conflict of Interest Statement**

593 The authors declare no competing interests.

594 References

- 595 1. APA. Diagnostic and Statistical Manual of Mental Disorders | Psychiatry Online
596 [Internet]. DSM Library. 2022 [cited 2024 Jul 30]. Available from:
597 <https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425787>
- 598 2. Salari N, Rasoulpoor S, Rasoulpoor S, Shohaimi S, Jafarpour S, Abdoli N, et al. The
599 global prevalence of autism spectrum disorder: a comprehensive systematic review
600 and meta-analysis. *Ital J Pediatr*. 2022 Jul 8;48(1):112.
- 601 3. Hodges H, Fealko C, Soares N. Autism spectrum disorder: definition, epidemiology,
602 causes, and clinical evaluation. *Transl Pediatr*. 2020 Feb;9(Suppl 1):S55–65.
- 603 4. McKenzie K, Milton M, Smith G, Ouellette-Kuntz H. Systematic Review of the
604 Prevalence and Incidence of Intellectual Disabilities: Current Trends and Issues. *Curr*
605 *Dev Disord Rep*. 2016 Jun 1;3(2):104–15.
- 606 5. Emerson E, Llewellyn G. Identifying children at risk of intellectual disability in
607 UNICEF’s multiple indicator cluster surveys: Cross-sectional survey. *Disabil Health*
608 *J*. 2021 Jan 1;14(1):100986.
- 609 6. Abubakar A, Ssewanyana D, Newton CR. A systematic review of research on autism
610 spectrum disorders in sub-Saharan Africa. *Behav Neurol*. 2016;2016.
- 611 7. Huang J, Zhu T, Qu Y, Mu D. Prenatal, Perinatal and Neonatal Risk Factors for
612 Intellectual Disability: A Systemic Review and Meta-Analysis. *PLOS ONE*. 2016 Apr
613 25;11(4):e0153655.
- 614 8. Lyall K, Croen L, Daniels J, Fallin MD, Ladd-Acosta C, Lee BK, et al. The Changing
615 Epidemiology of Autism Spectrum Disorders. *Annu Rev Public Health*.
616 2017;38(1):81–102.
- 617 9. Liu L, Wang J, Shao S, Luo X, Kong R, Zhang X, et al. Descriptive epidemiology of
618 prenatal and perinatal risk factors in a Chinese population with reading disorder. *Sci*
619 *Rep*. 2016 Nov 7;6:36697.
- 620 10. Jana A. Correlates of low birth weight and preterm birth in India. *PLOS ONE*. 2023
621 Aug 17;18(8):e0287919.
- 622 11. Walani SR. Global burden of preterm birth. *Int J Gynecol Obstet*. 2020;150(1):31–3.
- 623 12. Brown AS, Surcel HM, Hinkka-Yli-Salomäki S, Cheslack-Postava K, Bao Y,
624 Sourander A. Maternal Thyroid Autoantibody and Elevated Risk of Autism in a
625 National Birth Cohort. *Prog Neuropsychopharmacol Biol Psychiatry*. 2015 Mar
626 3;57:86–92.
- 627 13. Mankoski RE, Collins M, Ndosi NK, Mgalla EH, Sarwatt VV, Folstein SE. Etiologies
628 of Autism in a Case-series from Tanzania. *J Autism Dev Disord*. 2006 Nov
629 1;36(8):1039–51.
- 630 14. GUINCHAT V, THORSEN P, LAURENT C, CANS C, BODEAU N, COHEN D.
631 Pre-, peri- and neonatal risk factors for autism. *Acta Obstet Gynecol Scand*. Received:
632 9 September 2011, Accepted: 4 November 2011. 2012;91(3):287–300.
- 633 15. Croen LA, Najjar DV, Fireman B, Grether JK. Maternal and paternal age and risk of
634 autism spectrum disorders. *Arch Pediatr Adolesc Med*. 2007;161(4):334–40.

- 635 16. Taylor JL, Debost JCPG, Morton SU, Wigdor EM, Heyne HO, Lal D, et al. Paternal-
636 age-related de novo mutations and risk for five disorders. *Nat Commun*. 2019 Jul
637 10;10(1):3043.
- 638 17. Goldmann JM, Wong WSW, Pinelli M, Farrah T, Bodian D, Stittrich AB, et al.
639 Parent-of-origin-specific signatures of de novo mutations. *Nat Genet*. 2016
640 Aug;48(8):935–9.
- 641 18. Burger M, Hoosain M, Einspieler C, Unger M, Niehaus D. Maternal perinatal mental
642 health and infant and toddler neurodevelopment - Evidence from low and middle-
643 income countries. A systematic review. *J Affect Disord*. 2020 May 1;268:158–72.
- 644 19. de Menil V, Hoogenhout M, Kipkemoi P, Kamuya D, Eastman E, Galvin A, et al. The
645 NeuroDev Study: Phenotypic and Genetic Characterization of Neurodevelopmental
646 Disorders in Kenya and South Africa. *Neuron*. 2019 Jan 2;101(1):15–9.
- 647 20. Abubakar A, Van de Vijver F, Van Baar A, Mbonani L, Kalu R, Newton C, et al.
648 Socioeconomic status, anthropometric status, and psychomotor development of
649 Kenyan children from resource-limited settings: a path-analytic study. *Early Hum
650 Dev*. 2008 Sep;84(9):613–21.
- 651 21. Furuya-Kanamori L, Doi SA. LOGITTORISK: Stata module for conversion of
652 logistic regression output to differences and ratios of risk. *Stat Softw Compon*
653 [Internet]. 2021 Oct 16 [cited 2023 Sep 27]; Available from:
654 <https://ideas.repec.org/c/boc/bocode/s458886.html>
- 655 22. Walker CK, Krakowiak P, Baker A, Hansen RL, Ozonoff S, Hertz-Picciotto I.
656 Preeclampsia, Placental Insufficiency, and Autism Spectrum Disorder or
657 Developmental Delay. *JAMA Pediatr*. 2015 Feb 1;169(2):154–62.
- 658 23. Cha J, Sun X, Dey SK. Mechanisms of implantation: strategies for successful
659 pregnancy. *Nat Med*. 2012 Dec;18(12):1754–67.
- 660 24. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-
661 2010: age-period-cohort analysis. *BMJ*. 2013 Nov 7;347:f6564.
- 662 25. Getahun D, Fassett MJ, Peltier MR, Wing DA, Xiang AH, Chiu V, et al. Association
663 of Perinatal Risk Factors with Autism Spectrum Disorder. *Am J Perinatol*. 2017
664 Jul;07(3):295–304.
- 665 26. Kolevzon A, Gross R, Reichenberg A. Prenatal and Perinatal Risk Factors for Autism:
666 A Review and Integration of Findings. *JAMA Pediatr*. 2007;161(4):326–33.
- 667 27. Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, et al.
668 Maternal immune activation and abnormal brain development across CNS disorders.
669 *Nat Rev Neurol*. 2014 online;10:643.
- 670 28. Brucato M, Ladd-Acosta C, Li M, Caruso D, Hong X, Kaczaniuk J, et al. Prenatal
671 exposure to fever is associated with Autism Spectrum Disorder in the Boston Birth
672 Cohort. *Autism Res Off J Int Soc Autism Res*. 2017 Nov;10(11):1878–90.
- 673 29. Qiu C, Carter SA, Lin JC, Shi JM, Chow T, Desai VN, et al. Association of Labor
674 Epidural Analgesia, Oxytocin Exposure, and Risk of Autism Spectrum Disorders in
675 Children. *JAMA Netw Open*. 2023 Jul 21;6(7):e2324630.
- 676 30. Snow RW, Guerra CA, Noor AM, Myint HY, Hay SI. The global distribution of
677 clinical episodes of *Plasmodium falciparum* malaria. *Nature*. 2005
678 Mar;434(7030):214–7.

- 679 31. Bangirana P, Opoka RO, Boivin MJ, Idro R, Hodges JS, John CC. Neurocognitive
680 domains affected by cerebral malaria and severe malarial anemia in children. *Learn*
681 *Individ Differ*. 2016;46:38–44.
- 682 32. Maimburg RD, Bech BH, Vaeth M, Møller-Madsen B, Olsen J. Neonatal jaundice,
683 autism, and other disorders of psychological development. *Pediatrics*. 2010
684 Nov;126(5):872–8.
- 685 33. Meguid NA, Nashaat NH, Hashem HS, Khalil MM. Frequency of risk factors and
686 coexisting abnormalities in a population of Egyptian children with autism spectrum
687 disorder. *Asian J Psychiatry*. 2018 Feb;32:54–8.
- 688 34. Chen MH, Su TP, Chen YS, Hsu JW, Huang KL, Chang WH, et al. Is neonatal
689 jaundice associated with autism spectrum disorder, attention deficit hyperactivity
690 disorder, and other psychological development? A nationwide prospective study. *Res*
691 *Autism Spectr Disord*. 2014 Jun 1;8(6):625–32.
- 692 35. Cordero C, Schieve LA, Croen LA, Engel SM, Maria Siega-Riz A, Herring AH, et al.
693 Neonatal jaundice in association with autism spectrum disorder and developmental
694 disorder. *J Perinatol*. 2020 Feb;40(2):219–25.
- 695 36. Kujabi ML, Petersen JP, Pedersen MV, Parner ET, Henriksen TB. Neonatal jaundice
696 and autism spectrum disorder: a systematic review and meta-analysis. *Pediatr Res*.
697 2021 Nov;90(5):934–49.
- 698 37. Fujiwara T. Socioeconomic Status and the Risk of Suspected Autism Spectrum
699 Disorders Among 18-Month-Old Toddlers in Japan: A Population-Based Study. *J*
700 *Autism Dev Disord*. 2014 Jun 1;44(6):1323–31.
- 701 38. Gao Y, Wang T, Duan Z, Pu Y, Zhang J. The association between
702 neurodevelopmental and behavioral problems and tobacco smoke exposure among 3–
703 17 years old children. *Front Public Health* [Internet]. 2022 Aug 10 [cited 2024 Aug
704 6];10. Available from: [https://www.frontiersin.org/journals/public-](https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.881299/full)
705 [health/articles/10.3389/fpubh.2022.881299/full](https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2022.881299/full)
- 706 39. Ross EJ, Graham DL, Money KM, Stanwood GD. Developmental Consequences of
707 Fetal Exposure to Drugs: What We Know and What We Still Must Learn.
708 *Neuropsychopharmacology*. 2015 Jan;40(1):61–87.
- 709 40. Katz J, Reichenberg A, Kolevzon A. Prenatal and perinatal metabolic risk factors for
710 autism: a review and integration of findings from population-based studies. *Curr Opin*
711 *Psychiatry*. 2021;34(2):94–104.
- 712 41. Gardener H, Spiegelman D, Buka SL. Perinatal and Neonatal Risk Factors for
713 Autism: A Comprehensive Meta-analysis. *Pediatrics*. 2011;128(2):344–55.
- 714 42. Bolton PF, Murphy M, Macdonald H, Whitlock B, Pickles A, Rutter M. Obstetric
715 Complications in Autism: Consequences or Causes of the Condition? *J Am Acad*
716 *Child Adolesc Psychiatry*. 1997 Feb 1;36(2):272–81.
- 717 43. Sawires R, BATTERY J, Fahey M. A Review of Febrile Seizures: Recent Advances in
718 Understanding of Febrile Seizure Pathophysiology and Commonly Implicated Viral
719 Triggers. *Front Pediatr* [Internet]. 2022 Jan 13 [cited 2024 Jul 30];9. Available from:
720 <https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2021.801321/full>

- 721 44. Muglia LJ, Benhalima K, Tong S, Ozanne S. Maternal factors during pregnancy
722 influencing maternal, fetal, and childhood outcomes. *BMC Med.* 2022 Nov
723 1;20(1):418.
- 724 45. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Advanced parental age and autism risk in
725 children: a systematic review and meta-analysis. *Acta Psychiatr Scand.*
726 2017;135(1):29–41.
- 727 46. Sandin S, Schendel D, Magnusson P, Hultman C, Suren P, Susser E, et al. Autism risk
728 associated with parental age and with increasing difference in age between the
729 parents. *Mol Psychiatry.* 2016 May;21(5):693–700.
- 730 47. Gitobu CM, Gichangi PB, Mwanda WO. The effect of Kenya’s free maternal health
731 care policy on the utilization of health facility delivery services and maternal and
732 neonatal mortality in public health facilities. *BMC Pregnancy Childbirth.* 2018 Mar
733 27;18(1):77.
- 734 48. Moindi RO, Ngari MM, Nyambati VCS, Mbakaya C. Why mothers still deliver at
735 home: understanding factors associated with home deliveries and cultural practices in
736 rural coastal Kenya, a cross-section study. *BMC Public Health.* 2016 Feb 3;16:114.
- 737 49. Coxon K, Chisholm A, Malouf R, Rowe R, Hollowell J. What influences birth place
738 preferences, choices and decision-making amongst healthy women with
739 straightforward pregnancies in the UK? A qualitative evidence synthesis using a ‘best
740 fit’ framework approach. *BMC Pregnancy Childbirth.* 2017 Mar 31;17(1):103.
- 741 50. Andoy Galvan JA, Ramalingam PN, Patil SS, Bin Shobri MAS, Chinna K, Sahrir MS,
742 et al. Mode of delivery, order of birth, parental age gap and autism spectrum disorder
743 among Malaysian children: A case-control study. *Heliyon.* 2020 Oct;6(10):e05068.
- 744 51. Jones MB, Szatmari P. Stoppage rules and genetic studies of autism. *J Autism Dev*
745 *Disord.* 1988 Mar 1;18(1):31–40.
- 746 52. Elsabbagh M. Linking risk factors and outcomes in autism spectrum disorder: is there
747 evidence for resilience? *BMJ.* 2020 Jan 28;368:l6880.

